Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3597716rdf:typepubmed:Citationlld:pubmed
pubmed-article:3597716lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3597716lifeskim:mentionsumls-concept:C0345967lld:lifeskim
pubmed-article:3597716lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:3597716pubmed:issue3lld:pubmed
pubmed-article:3597716pubmed:dateCreated1987-7-24lld:pubmed
pubmed-article:3597716pubmed:abstractTextMurine monoclonal antibodies were used to identify tumor-cell membrane antigens on a new human mesothelioma cell line. Hybridomas were constructed by fusing SP2/0 mouse myeloma cells with spleen cells from Balb/C mice immunized by the human mesothelioma cell line MT-1. Hybridoma antibody was detected in 55/672 microculture wells that reacted to these MT-1 tumor cells by an indirect 125I-protein A binding assay. Six cultures produced antibody binding selectively to the MT-1 tumor cells but not to a human lymphoblastoid cell line. These six hybridomas were cloned: three were IgG and three were IgM antibodies. One monoclonal, MAb 45, reacted with 4 of 7 human mesothelioma cell lines but with only 1 of 11 carcinomas, 1 of 3 sarcomas, 4 of 11 melanomas, and 0 of 5 lymphoid lines. The other five monoclonals had a much broader cross-reactivity. Using an immunoperoxidase technique, MAb 45 bound to mixed-type malignant mesotheliomas but not to normal lung and pleura. The specificity of MAb 45 for diffuse mesotheliomas and the low cross-reactivity with carcinomas and normal adjacent tissues suggest that this monoclonal may be clinically useful.lld:pubmed
pubmed-article:3597716pubmed:languageenglld:pubmed
pubmed-article:3597716pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3597716pubmed:citationSubsetIMlld:pubmed
pubmed-article:3597716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3597716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3597716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3597716pubmed:statusMEDLINElld:pubmed
pubmed-article:3597716pubmed:monthMaylld:pubmed
pubmed-article:3597716pubmed:issn0271-9142lld:pubmed
pubmed-article:3597716pubmed:authorpubmed-author:ChengLLlld:pubmed
pubmed-article:3597716pubmed:authorpubmed-author:HolmesE CEClld:pubmed
pubmed-article:3597716pubmed:authorpubmed-author:AndersonT MTMlld:pubmed
pubmed-article:3597716pubmed:authorpubmed-author:SaxtonR ERElld:pubmed
pubmed-article:3597716pubmed:authorpubmed-author:KosakaC JCJlld:pubmed
pubmed-article:3597716pubmed:issnTypePrintlld:pubmed
pubmed-article:3597716pubmed:volume7lld:pubmed
pubmed-article:3597716pubmed:ownerNLMlld:pubmed
pubmed-article:3597716pubmed:authorsCompleteYlld:pubmed
pubmed-article:3597716pubmed:pagination254-61lld:pubmed
pubmed-article:3597716pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:meshHeadingpubmed-meshheading:3597716-...lld:pubmed
pubmed-article:3597716pubmed:year1987lld:pubmed
pubmed-article:3597716pubmed:articleTitleMonoclonal antibodies to human malignant mesothelioma.lld:pubmed
pubmed-article:3597716pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3597716lld:pubmed